Predictors of lithium response in bipolar disorder

Therapeutic Advances in Chronic Disease

Volumn 2, Issue 3, 2011, Pages 209-226

  Tighe, Sarah K ^a   Mahon, Pamela B ^a   Potash, James B ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

bipolar disorder; genetics; lithium; neuroimaging; predicting response

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; GLUTAMATE RECEPTOR; HALOPERIDOL; LAMOTRIGINE; LITHIUM DERIVATIVE; OLANZAPINE; PLACEBO; SYNDECAN 2; TRYPTOPHAN HYDROXYLASE; VALPROIC ACID; X BOX BINDING PROTEIN 1;

AGE; BDNF GENE; BIPOLAR DISORDER; BRAIN FUNCTION; COMBINATION CHEMOTHERAPY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE COURSE; DRUG EFFICACY; ELECTROCONVULSIVE THERAPY; ELECTROENCEPHALOGRAPHY; EVENT RELATED POTENTIAL; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC VARIABILITY; HEREDITY; HOSPITALIZATION; HUMAN; MAJOR DEPRESSION; MANIA; META ANALYSIS; MOLECULAR GENETICS; MONOTHERAPY; NEUROIMAGING; NTRK2 GENE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ODZ4 GENE; ONSET AGE; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; REVIEW; SDC2 GENE; TREATMENT DURATION; TREATMENT RESPONSE; XBP1 GENE;

EID: 79960049653     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622311399173     Document Type: Review

References (69)

1. Baastrup P.C. Poulsen J.C. Schou M. Thomsen K. Amdisen A. (1970) Prophylactic lithium: Double blind discontinuation in manic-depressive and recurrent-depressive disorders. Lancet 2: 326–330.
2. Baastrup P.C. Schou M. (1967) Lithium as a prophylactic agent. Its effect against recurrent depressions and manic-depressive psychosis. Arch Gen Psychiatry 16: 162–172.
3. Backlund L. Ehnvall A. Hetta J. Isacsson G. Agren H. (2009) Identifying predictors for good lithium response – a retrospective analysis of 100 patients with bipolar disorder using a life-charting method. Eur Psychiatry 24: 171–177.
4. Berghofer A. Alda M. Adli M. Baethge C. Bauer M. Bschor T. et al. (2008) Long-term effectiveness of lithium in bipolar disorder: A multicenter investigation of patients with typical and atypical features. J Clin Psychiatry 69: 1860–1868.
5. Bremer T. Diamond C. McKinney R. Shehktman T. Barrett T.B. Herold C. et al. (2007) The pharmacogenetics of lithium response depends upon clinical co-morbidity. Mol Diag Ther 11: 161–170.
6. Cade J.F. (1949) Lithium salts in the treatment of psychotic excitement. Med J Australia 2: 349–352.
7. Childs, B. (1999) Genetic Medicine. Johns Hopkins Univ. Press: Baltimore.
8. Coryell W. Akiskal H. Leon A.C. Turvey C. Solomon D. Endicott J. (2000) Family history and symptom levels during treatment for bipolar I affective disorder. Biol Psychiatry 47: 1034–1042.
9. Crossley N.A. Bauer M. (2007) Acceleration and augmentation of antidepressants with lithium for depressive disorders: Two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry 68: 935–940.
10. Davanzo P. Thomas M.A. Yue K. Oshiro T. Belin T. Strober M. et al. (2001) Decreased anterior cingulate myo-inositol/creatine spectroscopy resonance with lithium treatment in children with bipolar disorder. Neuropsychopharmacology 24: 359–369.
11. de Leon J. (2009) Pharmacogenomics: the promise of personalized medicine for CNS disorders. Neuropsychopharmacology 34: 159–172.
12. Dmitrzak-Weglarz M. Rybakowski J.K. Suwalska A. Skibinska M. Leszczynska-Rodziewicz A. Szczepankiewicz A. et al. (2008) Association studies of the BDNF and the NTRK 2 gene polymorphisms with prophylactic lithium response in bipolar patients. Pharmacogenomics 9: 1595–1603.
13. Duffy A. Alda M. Milin R. Grof P. (2007) A consecutive series of treated affected offspring of parents with bipolar disorder: Is response associated with the clinical profile? Can J Psychiatry 52: 369–376.
14. Dunner D.L. Fieve R.R. (1974) Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry 30: 229–233.
15. Foland L.C. Altshuler L.L. Sugar C.A. Lee A.D. Leow A.D. Townsend J. et al. (2008) Increased volume of the amygdala and hippocampus in bipolar patients treated with lithium. Neuroreport 19: 221–224.
16. Garnham J. Munro A. Slaney C. Macdougall M. Passmore M. Duffy A. et al. (2007) Prophylactic treatment response in bipolar disorder: Results of a naturalistic observation study. J Affect Disord 104: 185–190.
17. Geddes J.R. Burgess S. Hawton K. Jamison K. Goodwin G.M. (2004) Long-term lithium therapy for bipolar disorder: Systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry 161: 217–222.
18. Grof P. (2003) Selecting effective long-term treatment for bipolar patients: Monotherapy and combinations. J Clin Psychiatry 64: 53–61.
19. Grof P. Alda M. Grof E. Zvolsky P. Walsh M. (1994) Lithium response and genetics of affective disorders. J Affect Disord 32: 85–95.
20. Grof P. Duffy A. Cavazzoni P. Grof E. Garnham J. MacDougall M. et al. (2002) Is response to prophylactic lithium a familial trait? J Clin Psychiatry 63: 942–947.
21. Grof P. Muller-Oerlinghausen B. (2009) A critical appraisal of lithium's efficacy and effectiveness: the last 60 years. Bipolar Disord 11: 10–19.
22. Hegerl U. Ulrich G. Muller-Oerlinghausen B. (1987) Auditory evoked potentials and response to lithium prophylaxis. Pharmacopsychiatry 20: 213–216.
23. Hegerl U. Wulff H. Muller-Oerlinghausen B. (1992) Intensity dependence of auditory evoked potentials and clinical response to prophylactic lithium medication: A replication study. Psychiatry Res 44: 181–190.
24. Ikeda A. Kato N. Kato T. (2002) Possible relationship between electroencephalogram finding and lithium response in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 26: 903–907.
25. Juckel G. Mavrogiorgou P. Bredemeier S. Gallinat J. Frodl T. Schulz C. et al. (2004) Loudness dependence of primary auditory-cortex-evoked activity as predictor of therapeutic outcome to prophylactic lithium treatment in affective disorders – a retrospective study. Pharmacopsychiatry 37: 46–51.
26. Kakiuchi C. Iwamoto K. Ishiwata M. Bundo M. Kasahara T. Kusumi I. et al. (2003) Impaired feedback regulation of XBP 1 as a genetic risk factor for bipolar disorder. Nat Genet 35: 171–175.
27. Kakiuchi C. Kato T. (2005) Lithium response and -116C/G polymorphism of XBP 1 in Japanese patients with bipolar disorder. Int J Neuropsychopharm 8: 631–632.
28. Kato T. Inubushi T. Kato N. (2000) Prediction of lithium response by 31P-MRS in bipolar disorder. Int J Neuropsychopharm 3: 83–85.
29. Kim B. Kim C.Y. Lee M.J. Joo Y.H. (2009) Preliminary evidence on the association between XBP1-116C/G polymorphism and response to prophylactic treatment with valproate in bipolar disorders. Psychiatry Res 168: 209–212.
30. Kleindienst N. Engel R. Greil W. (2005) Which clinical factors predict response to prophylactic lithium? A systematic review for bipolar disorders. Bipolar Disord 7: 404–417.
31. Kusalic M. Engelsmann F. (1998) Predictors of lithium treatment responsiveness in bipolar patients. A two-year prospective study. Neuropsychobiology 37: 146–149.
32. Lievre A. Bachet J.B. Le Corre D. Boige V. Landi B. Emile J.F. et al. (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992–3995.
33. Lopez A.D. Murray C.C. (1998) The global burden of disease, 1990–2020 [news]. Nat Med 4: 1241–1243.
34. Lyoo I.K. Dager S.R. Kim J.E. Yoon S.J. Friedman S.D. Dunner D.L. et al. (2010) Lithium-induced gray matter volume increase as a neural correlate of treatment response in bipolar disorder: A longitudinal brain imaging study. Neuropsychopharmacology 35: 1743–1750.
35. Maj M. Starace F. Nolfe G. Kemali D. (1986) Minimum plasma lithium levels required for effective prophylaxis in DSM III bipolar disorder: A prospective study. Pharmacopsychiatry 19: 420–423.
36. Masui T. Hashimoto R. Kusumi I. Suzuki K. Tanaka T. Nakagawa S. et al. (2006 a) A possible association between the -116C/G single nucleotide polymorphism of the XBP 1 gene and lithium prophylaxis in bipolar disorder. Int J Neuropsychopharm 9: 83–88.
37. Masui T. Hashimoto R. Kusumi I. Suzuki K. Tanaka T. Nakagawa S. et al. (2006 b) Lithium response and Val66Met polymorphism of the brain-derived neurotrophic factor gene in Japanese patients with bipolar disorder. Psychiatric Genet 16: 49–50.
38. Masui T. Hashimoto R. Kusumi I. Suzuki K. Tanaka T. Nakagawa S. et al. (2008) A possible association between missense polymorphism of the breakpoint cluster region gene and lithium prophylaxis in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 32: 204–208.
39. McKnew D.H. Cytryn L. Buchsbaum M.S. Hamovit J. Lamour M. Rapoport J.L. et al. (1981) Lithium in children of lithium-responding parents. Psychiatry Res 4: 171–180.
40. Merikangas K.R. Akiskal H.S. Angst J. Greenberg P.E. Hirschfeld R.M. Petukhova M. et al. (2007) Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 64: 543–552.
41. Michelon L. Meira-Lima I. Cordeiro Q. Miguita K. Breen G. Collier D. et al. (2006) Association study of the INPP1, 5HTT, BDNF, AP-2beta and GSK-3beta GENE variants and restrospectively scored response to lithium prophylaxis in bipolar disorder. Neurosci Lett 403: 288–293.
42. Moore G.J. Bebchuk J.M. Parrish J.K. Faulk M.W. Arfken C.L. Strahl-Bevacqua J. et al. (1999) Temporal dissociation between lithium-induced changes in frontal lobe myo-inositol and clinical response in manic-depressive illness. Am J Psychiatry 156: 1902–1908.
43. Moore G.J. Bebchuk J.M. Wilds I.B. Chen G. Manji H.K. (2000) Lithium-induced increase in human brain grey matter. Lancet 356: 1241–1242.
44. Moore G.J. Cortese B.M. Glitz D.A. Zajac-Benitez C. Quiroz J.A. Uhde T.W. et al. (2009) A longitudinal study of the effects of lithium treatment on prefrontal and subgenual prefrontal gray matter volume in treatment-responsive bipolar disorder patients. J Clin Psychiatry 70: 699–705.
45. Okuma T. (1993) Effects of carbamazepine and lithium on affective disorders. Neuropsychobiology 27: 138–145.
46. Osby U. Brandt L. Correia N. Ekbom A. Sparen P. (2001) Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 58: 844–850.
47. Passmore M.J. Garnham J. Duffy A. MacDougall M. Munro A. Slaney C. et al. (2003) Phenotypic spectra of bipolar disorder in responders to lithium versus lamotrigine. Bipolar Disord 5: 110–114.
48. Perlis R.H. Smoller J.W. Ferreira M.A. McQuillin A. Bass N. Lawrence J. et al. (2009) A genomewide association study of response to lithium for prevention of recurrence in bipolar disorder. Am J Psychiatry 166: 718–725.
49. Pietras R.J. Fendly B.M. Chazin V.R. Pegram M.D. Howell S.B. Slamon D.J. (1994) Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9: 1829–1838.
50. Potash J.B. Willour V.L. Chiu Y. Simpson S.G. MacKinnon D.F. Pearlson G.D. et al. (2001) The familial aggregation of psychotic symptoms in bipolar disorder pedigrees. Am J Psychiatry 158: 1258–1264.
51. Reeves R.R. Struve F.A. Patrick G. (2001) Does EEG predict response to valproate versus lithium in patients with mania? Ann Clin Psychiatry 13: 69–73.
52. Rybakowski J.K. Suwalska A. Skibinska M. Dmitrzak-Weglarz M. Leszczynska-Rodziewicz A. Hauser J. (2007) Response to lithium prophylaxis: Interaction between serotonin transporter and BDNF genes. Am J Med Genet B Neuropsychiatr Genet 144B: 820–823.
53. Rybakowski J.K. Suwalska A. Skibinska M. Szczepankiewicz A. Leszczynska-Rodziewicz A. Permoda A. et al. (2005) Prophylactic lithium response and polymorphism of the brain-derived neurotrophic factor gene. Pharmacopsychiatry 38: 166–170.
54. Sarantidis D. Waters B. (1981) Predictors of lithium prophylaxis effectiveness. Prog Neuropsychopharmacol 5: 507–510.
55. Schou M. (1999) The early European lithium studies. Aust N Z J Psychiatry 33: S39–S47.
56. Schou M. Juel-Nielsen N. Stromgren E. Voldby H. (1954) The treatment of manic psychoses by the administration of lithium salts. J Neurol Neurosurg Psychiatry 17: 250–260.
57. Schulze T.G. Alda M. Adli M. Akula N. Ardau R. Bui E.T. et al. (2010) The International Consortium on Lithium Genetics (ConLiGen): An initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment. Neuropsychobiology 62: 72–78.
58. Serretti A. (2002) Lithium long-term treatment in mood disorders: Clinical and genetic predictors. Pharmacogenomics 3: 117–129.
59. Serretti A. Lilli R. Lorenzi C. Gasperini M. Smeraldi E. (1999) Tryptophan hydroxylase gene and response to lithium prophylaxis in mood disorders. J Psychiatr Res 33: 371–377.
60. Serretti A. Lilli R. Mandelli L. Lorenzi C. Smeraldi E. (2001) Serotonin transporter gene associated with lithium prophylaxis in mood disorders. Pharmacogenetics J 1: 71–77.
61. Small J.G. Milstein V. Malloy F.W. Klapper M.H. Golay S.J. Medlock C.E. (1998) Topographic EEG studies of mania. Clin Electroencephalogr 29: 59–66.
62. Small J.G. Milstein V. Malloy F.W. Medlock C.E. Klapper M.H. (1999) Clinical and quantitative EEG studies of mania. J Affect Disord 53: 217–224.
63. Tondo L. Baldessarini R.J. Floris G. (2001) Long-term clinical effectiveness of lithium maintenance treatment in types I and II bipolar disorders. Br J Psychiatry 178: S184–S190.
64. Tondo L. Hennen J. Baldessarini R.J. (2003) Rapid-cycling bipolar disorder: Effects of long-term treatments. Acta Psychiatr Scand 108: 4–14.
65. Usher J. Menzel P. Schneider-Axmann T. Kemmer C. Reith W. Falkai P. Gruber O. et al. (2010) Increased right amygdala volume in lithium-treated patients with bipolar I disorder. Acta Psychiatr Scand 121: 119–124.
66. Yang Y.Y. (1985) Prophylactic efficacy of lithium and its effective plasma levels in Chinese bipolar patients. Acta Psychiatr Scand 71: 171–175.
67. Yazici O. Kora K. Ucok A. Tunali D. Turan N. (1999) Predictors of lithium prophylaxis in bipolar patients. J Affect Disord 55: 133–142.
68. Yildiz A. Vieta E. Leucht S. Baldessarini R.J. (2011) Efficacy of antimanic treatments: Meta-analysis of randomized, controlled trials. Neuropsychopharmacology 36: 375–389.
69. Yucel K. McKinnon M.C. Taylor V.H. Macdonald K. Alda M. Young L.T. et al. (2007) Bilateral hippocampal volume increases after long-term lithium treatment in patients with bipolar disorder: A longitudinal MRI study. Psychopharmacology 195: 357–367.